Affordable Access

Publisher Website

Quality-adjusted survival analysis of malignant glioma patients

Authors
Journal
Controlled Clinical Trials
0197-2456
Publisher
Elsevier
Publication Date
Volume
18
Issue
4
Identifiers
DOI: 10.1016/s0197-2456(96)00243-7
Keywords
  • Quality Of Life
  • Survival Analysis
  • Glioma
Disciplines
  • Biology
  • Medicine

Abstract

Abstract The goal of therapeutic intervention in oncology patients is to prolong survival without compromising its quality. Definition and measurement of quality are quite difficult. This article discusses the statistical techniques for quantifying quality survival that have been used in brain tumor patients. These techniques assume either that all patients have equivalent baseline quality of life when both disease-related symptoms and toxicities are absent, or that the length of time with a predetermined level of impairment is equivalent to death. These models do not fit the heterogeneous symptoms experienced by patients with malignant brain tumors. We propose a model that incorporates the baseline states with transitions to different levels of severity that indicate improvement and/or declines in physical and cognitive functioning of brain tumor patients. The length of time spent in each state is observed and weighted by using predetermined utilities. The weighted time spent in each state is aggregated over all states into a quality-time of survival metric (QTIME). This QTIME model was applied to a previously published, randomized clinical trial of different radiation doses in malignant brain tumor patients.

There are no comments yet on this publication. Be the first to share your thoughts.

Statistics

Seen <100 times
0 Comments

More articles like this

Quality-adjusted survival analysis of malignant gl...

on Controlled clinical trials August 1997

Quality-adjusted survival analysis of malignant gl...

on International Journal of Radia... Feb 01, 1995

Quality-adjusted survival analysis.

on Journal of Clinical Oncology March 1991
More articles like this..